



Herbal Roll-On Therapy: A Natural Approach to Headache Management

R. Nishitha, P. Ruchitha, P. Soumya, C. Vaishnavi, D. Sai Smrithi, P. Vivek Sagar and P. Ravi Kumar*

Department of Pharmacognosy, Sarojini Naidu Vanitha Pharmacy Maha Vidyalaya (Co-Ed.), Osmania University, Tarnaka-500017, Secunderabad, Telangana, India

Received: 25 Mar 2026 / Accepted: 7 Apr 2026 / Published online: 1 Jul 2026

*Corresponding Author Email: ravipharma18@gmail.com

Abstract

Headache and migraine are among the most disabling neurological conditions globally, affecting over 50% of the world population and imposing a substantial socioeconomic burden. While conventional pharmacotherapy offers symptomatic relief, the prolonged use of analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) is associated with significant adverse effects including gastric ulceration, hepatotoxicity, and medication-overuse headache. The present study aimed to formulate, develop, and evaluate a polyherbal roll-on topical preparation incorporating peppermint oil, eucalyptus oil, lavender oil, rosemary oil, clove oil, camphor, jojoba oil, glycerine, and vitamin E for the management of headache, migraine, stress, nasal congestion, and mild musculoskeletal pain. The formulation was prepared by a simple blending method. Physicochemical evaluation included organoleptic properties, pH determination, homogeneity, spreadability, skin irritation testing, microbial limit testing, stability under ICH-recommended conditions, and container integrity assessment. The roll-on demonstrated a pleasant aromatic odor, clear homogeneous appearance, skin-compatible pH (5.5–7.0), excellent spreadability, and absence of irritation. No microbial growth or leakage was recorded. Stability testing under accelerated conditions ($40 \pm 2^\circ\text{C}/75\% \text{ RH}$) confirmed no significant changes in physical or chemical characteristics. The developed herbal roll-on represents a safe, stable, economical, and user-friendly natural alternative for topical headache and pain management. Its synergistic phytochemical composition offers multi-modal therapeutic action, making it a promising candidate for further clinical investigation.

Keywords

Herbal Roll-On, Essential Oils, Headache, Migraine, Aromatherapy, Topical Formulation, Peppermint Oil, Eucalyptus Oil, Lavender Oil, Pain Management, Phytotherapy.

1. INTRODUCTION

1.1 Global Burden of Headache Disorders

Headache disorders represent one of the most common and debilitating neurological conditions affecting the global population. According to the World Health Organization (WHO, 2024), nearly half of the adult population has experienced at least one headache episode in the past year, and

approximately 1.7–4% suffer from chronic daily headache. Migraine alone affects over one billion individuals worldwide, ranking as the second-leading cause of years lived with disability (YLDs) globally (GBD 2019 Diseases and Injuries Collaborators, 2020). Tension-type headache (TTH) is the most prevalent form, with a lifetime prevalence of 78% in the general population (Stovner et al., 2022).

The socioeconomic impact of headache disorders is enormous. Direct costs related to medical consultations, diagnostic investigations, and pharmacotherapy, combined with indirect costs arising from reduced workplace productivity and absenteeism, translate into substantial national healthcare expenditures. In India alone, headache disorders account for a significant proportion of outpatient neurology consultations, necessitating affordable and accessible treatment options (Rao et al., 2017).

1.2 Limitations of Conventional Pharmacotherapy

Conventional management of headache and migraine relies predominantly on pharmacological agents including NSAIDs (ibuprofen, naproxen, aspirin), acetaminophen, triptans, ergot alkaloids, and preventive agents such as beta-blockers, anticonvulsants, and antidepressants (Lipton et al., 2020). While these agents provide effective symptomatic relief, their prolonged use is associated with a spectrum of adverse effects. NSAIDs are linked to gastrointestinal irritation, peptic ulceration, renal impairment, and cardiovascular risk (Rang et al., 2020). Triptans may cause vasoconstriction and are contraindicated in patients with cardiovascular disease. A paradoxical consequence of excessive analgesic use is medication-overuse headache (MOH), also termed analgesic rebound headache, which has become a significant clinical challenge (Diener et al., 2019).

These limitations have spurred growing interest in complementary and alternative medicine (CAM), particularly herbal and aromatherapeutic approaches that offer symptomatic relief with a more favorable safety profile.

1.3 Herbal Medicine and Aromatherapy in Pain Management

Phytotherapy and aromatherapy have been integral to traditional medicine systems—including Ayurveda, Traditional Chinese Medicine (TCM), and Unani—for millennia. Essential oils extracted from medicinal plants constitute a rich repository of bioactive phytoconstituents with analgesic, anti-inflammatory, antispasmodic, and anxiolytic properties (Bakkali et al., 2008; Edris, 2007). The inhalation or topical application of volatile essential oil components facilitates rapid penetration through the stratum corneum and olfactory pathways, eliciting both local and systemic therapeutic responses (Ali et al., 2015).

Contemporary pharmacological research has validated the empirical use of several essential oils. Menthol from peppermint (*Mentha piperita*) activates TRPM8 cold-sensitive receptors, producing analgesic and cooling effects. Eucalyptol (1,8-

cineole) from eucalyptus oil inhibits inflammatory cytokines and NF- κ B signaling. Linalool from lavender modulates GABAergic neurotransmission to produce anxiolysis and sedation. Eugenol from clove oil inhibits prostaglandin synthesis analogous to NSAIDs. These molecular mechanisms substantiate the therapeutic rationale for polyherbal topical formulations (Gobel et al., 1994; Tisserand & Young, 2014).

1.4 Topical Roll-On Drug Delivery Systems

Topical drug delivery offers several pharmacokinetic and pharmacodynamic advantages over oral or parenteral routes. Local application avoids first-pass hepatic metabolism, reduces systemic adverse effects, and enables targeted delivery to the site of action (Prausnitz & Langer, 2008). Roll-on applicators, equipped with a precision ball-tip mechanism, are particularly advantageous for topical herbal preparations. They ensure consistent dose delivery, minimize manual contamination, are portable and user-friendly, and allow self-administration. The roll-on format is increasingly recognized in the cosmeceutical and herbal pharmaceutical industries as an optimal delivery system for volatile oil-based formulations (Garg et al., 2010).

The present review comprehensively examines the scientific basis, formulation considerations, pharmacological properties, evaluation parameters, research gaps, and future scope of herbal roll-on preparations for headache and pain management, with specific reference to the multi-component formulation under study.

2. PHYTOPHARMACOLOGICAL PROFILE OF FORMULATION INGREDIENTS

2.1 Peppermint Oil (*Mentha piperita* L.)

Peppermint oil is steam-distilled from the aerial parts of *Mentha piperita* L. (Lamiaceae). The principal bioactive constituent is L-menthol (35–45%), followed by menthone (10–35%), menthyl acetate, menthofuran, and 1,8-cineole (McKay & Blumberg, 2006). Menthol selectively activates the TRPM8 (transient receptor potential melastatin-8) ion channel, producing a characteristic cooling sensation and analgesic effect independent of temperature change. This mechanism underlies its clinical utility in tension-type headache.

A randomized controlled trial by Göbel et al. (1994) demonstrated that topical application of 10% peppermint oil in ethanol to the forehead and temples was as effective as 1000 mg of acetaminophen in reducing tension headache intensity, with a faster onset of action. Subsequent studies have confirmed significant reductions in

headache severity scores with peppermint oil application within 15–30 minutes (Borhani Haghighi et al., 2010). Additionally, peppermint oil exhibits antimicrobial activity against a broad spectrum of bacteria and fungi by disrupting membrane permeability (Isçan et al., 2002).

2.2 Eucalyptus Oil (*Eucalyptus globulus* Labill.)

Eucalyptus oil is derived from the leaves of *Eucalyptus globulus* (Myrtaceae) and contains predominantly 1,8-cineole (eucalyptol; 70–85%), together with α -pinene, limonene, and β -cymene (Dhakad et al., 2018). Eucalyptol is a well-characterized anti-inflammatory agent that inhibits arachidonic acid metabolism, suppresses tumor necrosis factor- α (TNF- α), interleukin-1 β (IL-1 β), and nuclear factor-kappa B (NF- κ B) signaling pathways (Jürgens et al., 2003). These properties confer significant analgesic and anti-inflammatory activity relevant to headache management.

Eucalyptus oil exerts powerful decongestant effects by reducing nasal mucosal congestion through vasoconstriction and ciliary stimulation, making it especially beneficial in headaches associated with sinusitis and upper respiratory congestion (Kehrl et al., 2004). Its broad-spectrum antimicrobial and antioxidant activities further enhance the formulation's microbiological safety profile.

2.3 Lavender Oil (*Lavandula angustifolia* Mill.)

Lavender essential oil, obtained by steam distillation of flowers of *Lavandula angustifolia* (Lamiaceae), contains linalool (25–45%) and linalyl acetate (25–40%) as dominant constituents, along with 1,8-cineole, camphor, and β -ocimene (Cavanagh & Wilkinson, 2002). Linalool modulates GABA-A receptor activity, exhibiting significant anxiolytic, sedative, and antinociceptive effects without the dependence potential associated with benzodiazepines (Linck et al., 2009).

A placebo-controlled trial by Sasannejad et al. (2012) demonstrated that inhaled lavender oil significantly reduced headache severity in migraine patients compared to placebo. Lavender oil also reduces cortisol levels and sympathetic nervous system activity, providing stress-relieving and relaxation effects critical in stress-induced and tension-type headaches (Field et al., 2005). Cavanagh and Wilkinson (2002) comprehensively reviewed lavender's biological activities, confirming its antimicrobial, antifungal, antioxidant, and anti-inflammatory properties.

2.4 Rosemary Oil (*Rosmarinus officinalis* L.)

Rosemary essential oil from *Rosmarinus officinalis* L. (Lamiaceae) contains 1,8-cineole (40–50%), camphor (10–25%), α -pinene (15–25%), and borneol. It possesses anti-inflammatory properties mediated

through inhibition of COX-2 enzyme activity and downregulation of pro-inflammatory cytokines (Takaki et al., 2008). Rosemary oil also acts as a rubefacient, promoting local blood circulation and alleviating musculoskeletal pain by enhancing cutaneous perfusion.

Rosmarinus officinalis has been reported to enhance cognitive performance and improve mood, effects attributed to its cholinesterase-inhibiting activity and modulation of cerebral blood flow (Moss et al., 2010). Its antioxidant activity, primarily from rosmarinic acid and carnosic acid, contributes to formulation stability by preventing oxidative degradation of co-ingredients.

2.5 Clove Oil (*Syzygium aromaticum* L.)

Clove oil, derived from the flower buds of *Syzygium aromaticum* (Myrtaceae), is predominantly composed of eugenol (70–90%), β -caryophyllene (5–12%), and eugenyl acetate (Chaieb et al., 2007). Eugenol is a potent analgesic and anti-inflammatory agent with mechanisms comparable to NSAIDs: it inhibits COX-1 and COX-2 enzymes, reduces prostaglandin E2 synthesis, and activates TRPV1 receptors to produce transient analgesia followed by desensitization (Daniel et al., 2009). Eugenol also exhibits local anesthetic activity by blocking voltage-gated sodium channels, useful in alleviating acute pain.

Clove oil's strong antimicrobial activity against *Staphylococcus aureus*, *Candida albicans*, and other pathogens contributes to the microbiological safety of the formulation (Chaieb et al., 2007). The concentration of clove oil (0.10 ml) in the formulation is carefully controlled, as high concentrations of eugenol may be cytotoxic.

2.6 Camphor

Camphor (2-bornanone), a bicyclic monoterpene obtained from *Cinnamomum camphora* and synthetically produced, acts as a TRPV1 and TRPM8 receptor agonist-antagonist, producing a complex cooling-then-warming sensation on skin application (Sherkheli et al., 2010). This dual sensory effect enhances the perceived analgesic and counter-irritant action of the formulation. Camphor also penetrates the stratum corneum efficiently, promoting transdermal permeation of co-ingredients. Its mild antibacterial and antifungal activities contribute to the preservation of the formulation.

2.7 Jojoba Oil (*Simmondsia chinensis*)

Jojoba oil, a liquid wax ester extracted from seeds of *Simmondsia chinensis* (Buxaceae), serves as the primary carrier vehicle in this formulation. Unlike triglyceride-based carrier oils, jojoba consists predominantly of long-chain esters (C20–C22 wax

esters) that closely mimic human sebum, rendering it non-comedogenic, oxidatively stable, and excellently biocompatible (Pazyar et al., 2013). Its good skin penetration, non-greasy texture, and resistance to rancidity make it an ideal vehicle for volatile essential oils. Jojoba oil also possesses anti-inflammatory properties mediated via inhibition of 5-lipoxygenase.

2.8 Glycerine and Vitamin E

Glycerine (glycerol), a trihydric alcohol, functions as a humectant and co-solvent in the formulation. It attracts moisture from the dermis to the epidermis, maintaining skin hydration and preventing dryness during and after roll-on application. At concentrations of 5–20%, glycerine improves skin texture and reduces transepidermal water loss (TEWL) (Fluhr et al., 2008).

Vitamin E (α -tocopherol) serves a dual role: as a potent lipophilic antioxidant protecting essential oils from oxidative degradation, thereby extending formulation shelf-life, and as a skin-conditioning agent that mitigates inflammation and promotes

epithelial repair (Thiele et al., 2005). Its inclusion at 0.10 ml ensures formulation stability without altering the physicochemical properties.

3. FORMULATION DESIGN AND DEVELOPMENT

3.1 Rationale for Polyherbal Approach

The polyherbal formulation strategy is grounded in the concept of synergism, wherein the combined phytochemical action of multiple botanical ingredients produces an effect greater than the sum of individual components (Wagner & Ulrich-Merzenich, 2009). The combination of menthol (analgesic/cooling), eucalyptol (anti-inflammatory/decongestant), linalool (anxiolytic/sedative), eugenol (analgesic/anti-inflammatory), and camphor (counter-irritant/penetration enhancer) creates a multi-modal therapeutic system addressing the neurological, vascular, and psychological dimensions of headache and migraine.

3.2 Formulation Composition

Table 1: Formulation Composition and Pharmacological Roles of Each Ingredient

Ingredient	Quantity (per 10 mL)	Pharmacological Role	Concentration (%)
Peppermint Oil	0.50 mL	Analgesic, Cooling, Antimicrobial	5.0%
Eucalyptus Oil	0.30 mL	Anti-inflammatory, Decongestant	3.0%
Lavender Oil	0.30 mL	Anxiolytic, Sedative, Anti-inflammatory	3.0%
Rosemary Oil	0.30 mL	Anti-inflammatory, Rubefacient	3.0%
Clove Oil	0.10 mL	Analgesic, Local Anesthetic	1.0%
Camphor	0.20 g	Counter-irritant, Penetration Enhancer	2.0%
Jojoba Oil	7.50 mL	Carrier Base, Emollient	75.0%
Glycerine	0.50 mL	Humectant, Co-solvent	5.0%
Vitamin E	0.10 mL	Antioxidant, Skin-conditioning	1.0%

3.3 Method of Preparation

The formulation was prepared using a simple cold-blending method, which is advantageous for preserving the volatile bioactive constituents of essential oils that may be degraded by heat. Jojoba oil was measured accurately and transferred to a clean, dry glass beaker. Camphor was added to the jojoba oil and dissolved under continuous magnetic stirring at room temperature until a clear solution was obtained. The five essential oils (eucalyptus, peppermint, lavender, rosemary, and clove) were added sequentially with gentle stirring to ensure complete miscibility. Glycerine was incorporated

slowly, followed by vitamin E. The resulting preparation was a clear, homogeneous, aromatic solution. The final preparation was transferred into sterile 10 mL roll-on glass containers equipped with stainless steel ball applicators and sealed with appropriate caps (Bauer et al., 2001).

The cold-blending method is particularly suitable for oil-in-oil and oil-solvent systems where all components are mutually miscible. This eliminates the need for emulsifiers, preservatives, or heat processing, resulting in a simpler, cleaner formulation profile and reduced regulatory complexity.

4. EVALUATION PARAMETERS AND RESULTS

4.1 Organoleptic Properties

Organoleptic evaluation encompasses the sensory assessment of a pharmaceutical preparation and forms the first line of quality assessment. The developed roll-on presented a clear, colorless to pale-yellow solution with a characteristic pleasant, refreshing aromatic odor attributed to the blend of essential oils. The formulation exhibited a light, non-viscous consistency suitable for roll-on application. No turbidity, precipitates, or phase separation were detected. These results are consistent with published literature on essential oil-based topical preparations (Garg et al., 2010).

4.2 pH Determination

The pH of the formulation (5.5–7.0) falls within the physiological skin pH range of 4.5–7.0, consistent with what is widely reported as optimal for topical preparations. Human skin maintains a slightly acidic pH (“acid mantle”) that supports the cutaneous microbiome and the integrity of the epidermal barrier. Formulations with pH values outside this range may cause irritation, compromise the skin barrier, or alter the ionization state of active constituents, reducing their absorption. The observed pH confirms that the formulation is unlikely to disrupt normal skin physiology (Fluhr et al., 2008; Lambers et al., 2006).

4.3 Homogeneity and Spreadability

Homogeneity testing confirmed a smooth, uniform preparation without visible particulate matter, aggregates, or grittiness. Uniform distribution of ingredients ensures consistent dose delivery with each application. Spreadability assessment using the glass slide method demonstrated excellent gliding properties, enabling efficient and effortless application over the forehead, temples, and other targeted areas. Good spreadability is critical for patient acceptance and compliance with topical formulations (Marriott et al., 2010).

4.4 Skin Irritation Testing

The formulation was applied to the inner forearm and observed over 24–48 hours for signs of contact dermatitis including erythema, edema, pruritus, and vesiculation. No adverse cutaneous reactions were detected in any subject, demonstrating the dermal compatibility of the formulation. This favorable safety profile may be attributed to the skin-friendly pH, the non-comedogenic nature of jojoba oil, the moisturizing effect of glycerine, and the anti-inflammatory properties of lavender and eucalyptus

oils. The concentration of potentially sensitizing components, particularly eugenol (clove oil) and menthol (peppermint oil), was maintained within safe limits as specified by the International Fragrance Association (IFRA) guidelines (Tisserand & Young, 2014).

4.5 Stability Studies

Stability evaluation followed ICH Q1A(R2) guidelines. The formulation was stored under three conditions: (a) refrigerated (2–8°C), (b) ambient/room temperature ($25 \pm 2^\circ\text{C}/60\% \text{ RH}$), and (c) accelerated conditions ($40 \pm 2^\circ\text{C}/75\% \text{ RH}$) for three months. Parameters monitored included appearance, color, odor, pH, homogeneity, and leakage at 0, 30, 60, and 90 days. No significant changes in any parameter were observed across all storage conditions, indicating excellent physical and chemical stability. The stability of the formulation is attributed to the antioxidant protection conferred by vitamin E and rosemary oil (rosmarinic acid), the chemical stability of the carrier (jojoba wax esters), and the inherent antimicrobial activity of the essential oils limiting microbial degradation (ICH, 2003).

4.6 Microbial Limit Testing

Microbial limit testing was performed according to USP and IP pharmacopoeial standards. The formulation was inoculated on nutrient agar (for total aerobic microbial count) and Sabouraud dextrose agar (for total yeast and mold count) at 37°C for 72 hours. No microbial growth was observed, demonstrating the inherent antimicrobial self-preservation capacity of the formulation. The antimicrobial efficacy is primarily contributed by peppermint oil, eucalyptus oil, clove oil (eugenol), and camphor, all of which possess well-documented broad-spectrum antimicrobial activity against common contaminant organisms including *S. aureus*, *E. coli*, *Pseudomonas aeruginosa*, *Aspergillus niger*, and *Candida albicans* (Bakkali et al., 2008; Chaieb et al., 2007).

4.7 Leakage Test

Container integrity is critical for maintaining formulation sterility, preventing product loss, and ensuring accurate dose delivery. The roll-on containers were subjected to leakage testing in both upright and inverted positions for 24 hours. No leakage was observed from any container, confirming the adequacy of the sealing mechanism and the suitability of the selected packaging system for the formulation’s viscosity and chemical composition.

4.8 Summary of Evaluation Results

Table 2: Summary of Evaluation Results

Parameter	Observation	Inference
Organoleptic Properties	Pleasant odor; clear, homogeneous appearance	Acceptable
pH	5.5–7.0	Skin-compatible
Homogeneity	Smooth and uniform; no phase separation	Passed
Spreadability	Easy, effortless spreading on skin surface	Good
Skin Irritation Test	No erythema, edema, or pruritus	Safe
Stability (Accelerated)	No changes at 40 ± 2°C / 75% RH over 3 months	Stable
Microbial Limit Test	No microbial or fungal growth detected	Safe / Self-preserved
Leakage Test	No leakage (upright and inverted positions)	Passed

5. MECHANISM OF ACTION AND SYNERGISTIC EFFECTS

The therapeutic efficacy of the herbal roll-on formulation arises from the complementary and synergistic pharmacological mechanisms of its constituent essential oils operating through multiple molecular targets simultaneously. This polymodal approach is particularly advantageous in complex conditions such as migraine and tension-type headache, which involve neurogenic inflammation, sensitization of peripheral and central nociceptors, vascular dysregulation, and psychological stress.

5.1 Peripheral Analgesia

Menthol and camphor activate TRPM8 cold receptors while simultaneously desensitizing TRPV1 heat/pain receptors, producing a counter-irritant analgesic effect at the site of application (McKay & Blumberg, 2006; Sherkheli et al., 2010). Eugenol from clove oil inhibits COX enzymes and blocks sodium channels, reducing peripheral sensitization of nociceptors. The combined action of these constituents significantly attenuates the transmission of pain signals from the trigeminal nerve endings in the pericranial and facial tissues.

5.2 Anti-inflammatory Action

Eucalyptol, linalool, rosmarinic acid, and β -caryophyllene act synergistically to suppress the NF- κ B inflammatory signaling cascade, inhibit COX-1/2 enzymes, and reduce the release of pro-inflammatory mediators (PGE₂, TNF- α , IL-1 β , IL-6) at the meningeal and pericranial levels (Juergens et al., 2003; Takaki et al., 2008). This broad anti-inflammatory action is relevant to both migraine (which involves neurogenic meningeal inflammation) and tension-type headache (associated with pericranial myofascial inflammation).

5.3 Central and Psychophysiological Effects

Upon inhalation during application, volatile constituents of lavender (linalool, linalyl acetate), rosemary (1,8-cineole), and peppermint (menthol) access the olfactory system and limbic structures, modulating the hypothalamic-pituitary-adrenal (HPA) axis and reducing cortisol secretion (Field et

al., 2005; Perry & Perry, 2006). This neuroendocrine modulation reduces the psychological stress component of tension headache and migraine. The anxiolytic and sedative properties of lavender also facilitate sleep, promoting the natural recovery process.

5.4 Nasal Decongestant Effects

Eucalyptol, camphor, and menthol exert decongestant effects through stimulation of cold receptors in the nasal mucosa and promotion of mucociliary clearance, reducing sinus pressure and associated headache in sinusitis-related conditions (Kehrl et al., 2004). This addresses the subset of headaches triggered by nasal congestion and upper respiratory infections.

6. RESEARCH GAPS AND FUTURE SCOPE

6.1 Identified Research Gaps

Despite the promising results of the present formulation study and the substantial body of ethnopharmacological and preclinical evidence supporting herbal essential oils in headache management, several critical research gaps remain:

- **Absence of Clinical Trial Data:** The current formulation has not been subjected to randomized, double-blind, placebo-controlled clinical trials (RCTs) in human subjects. Clinical evidence for the formulation as a composite product is lacking, even though individual components (particularly peppermint oil) have demonstrated clinical efficacy (Göbel et al., 1994; Borhani Haghighi et al., 2010).
- **Limited Pharmacokinetic Data:** Quantitative data on transdermal permeation rates, percutaneous absorption profiles, and plasma concentrations of key bioactives (menthol, eucalyptol, linalool) following roll-on application are absent. Such data are essential for establishing dosing regimens and bioavailability claims.
- **Absence of In Vitro Permeation Studies:** Franz diffusion cell studies using excised human or synthetic skin membranes would provide

mechanistic insight into skin penetration and release kinetics of the active constituents.

- **No Standardization of Essential Oil Composition:** Essential oil composition varies significantly with geographical origin, harvest season, distillation conditions, and storage. The formulation lacks batch-to-batch standardization based on chemical fingerprinting (GC-MS analysis) of key marker compounds.
- **No Evaluation of Synergistic Interactions:** While synergism is postulated, no isobolographic or checkerboard assay studies have been conducted to quantify the synergistic analgesic and anti-inflammatory interactions among the essential oil components.
- **Absence of Long-Term Safety Data:** Repeated dermal sensitization studies, phototoxicity studies, and long-term dermal toxicology assessments (sub-chronic and chronic) conforming to OECD test guidelines have not been performed.
- **Paediatric and Geriatric Safety:** The safety of menthol and camphor-containing preparations in children (especially under age 2) is a known concern (Patel & Bhatt, 2016). Age-specific safety and dosing data are absent from the current study.
- **Comparative Efficacy Studies:** Head-to-head comparisons with commercially available herbal roll-ons (Tiger Balm, Amrutanjan, Vicks VapoRub) and with standard pharmacotherapy (acetaminophen, ibuprofen) have not been conducted.

6.2 FUTURE SCOPE OF RESEARCH

The present formulation establishes a foundation for a structured research programme with multiple exciting avenues:

- **Phase I/II Clinical Trials:** Conduct double-blind, randomized, placebo-controlled trials measuring headache severity (VAS score), frequency, and duration in patients with episodic tension-type headache and migraine (without aura). Patient-reported outcomes including quality of life (HIT-6 score) should be incorporated.
- **Nanotechnology-Enhanced Formulations:** Encapsulation of essential oils in nanostructured lipid carriers (NLCs), nanoemulsions, or solid lipid nanoparticles (SLNs) could enhance transdermal permeability, reduce volatility losses, mask intense odors, and enable controlled release of bioactives (Gupta et al., 2020).

- **GC-MS Chemical Standardization:** Implement gas chromatography-mass spectrometry (GC-MS) profiling and quantitative analysis of marker compounds (menthol, eucalyptol, linalool, eugenol) in each batch to establish quality specifications and ensure therapeutic consistency.
- **Permeation Enhancement Strategies:** Investigate chemical penetration enhancers (oleic acid, propylene glycol, terpenes) or physical enhancement methods (microneedle pre-treatment, iontophoresis) to augment transdermal delivery of hydrophilic bioactives.
- **Stability-Indicating Analytical Methods:** Develop and validate HPLC-UV or GC-FID stability-indicating assay methods for quantitative determination of key marker compounds during stability studies, providing chemical stability data in addition to physical observations.
- **Comparative Formulation Optimization:** Apply Box-Behnken or Central Composite Design (response surface methodology) to optimize essential oil concentrations and achieve maximum analgesic and anti-inflammatory responses while minimizing irritation potential.
- **Ethnobotanical Survey Integration:** Conduct systematic ethnobotanical surveys among traditional healers in India to identify additional indigenous plants with headache-relieving potential, which could be integrated into future polyherbal roll-on formulations.
- **Digital Health Integration:** Future research could evaluate the complementary use of herbal roll-ons alongside digital health interventions (mindfulness apps, biofeedback) in a comprehensive non-pharmacological headache management protocol.

7. DISCUSSION

The herbal roll-on formulation described in this study represents a pragmatic convergence of traditional ethnopharmacological knowledge and contemporary pharmaceutical formulation science. The selection of ingredients reflects a deliberate multi-target pharmacological strategy: menthol and eugenol for peripheral analgesia, eucalyptol and linalool for anti-inflammatory and anxiolytic effects, camphor for penetration enhancement and counter-irritation, and jojoba oil and vitamin E for optimal dermal delivery and stability.

Compared to existing commercial topical preparations such as Tiger Balm (containing camphor, menthol, cajuput oil, and clove oil) and Amrutanjan Pain Balm (containing menthol,

eucalyptus oil, and turpentine oil), the present formulation offers several advantages: it is free from petrolatum-based carriers (avoiding comedogenicity), incorporates lavender and rosemary oils for neuropsychological benefits, and employs jojoba—a biologically compatible, non-rancid carrier—as the vehicle (Pazyar et al., 2013).

The observed physicochemical results are highly consistent with published herbal topical formulation studies. Sharma et al. (2020) reported similar pH (5.8–6.5) and stability profiles for peppermint-eucalyptus roll-ons. Raut and Karuppaiyil (2014) demonstrated the antimicrobial self-preserving capacity of essential oil blends containing peppermint, clove, and eucalyptus at comparable concentrations, supporting the microbiological safety data presented herein.

A particularly noteworthy aspect of this formulation is its potential role in medication-overuse headache prevention. As a non-pharmacological, non-analgesic topical preparation, it does not contribute to the development of MOH and may serve as a viable adjunct or alternative therapy in patients at risk of analgesic overuse (Diener et al., 2019). This positions herbal roll-ons within the growing paradigm of non-pharmacological headache management endorsed by the International Headache Society.

8. CONCLUSION

The present study successfully developed and evaluated a polyherbal roll-on formulation comprising nine pharmaceutical-grade ingredients with complementary pharmacological mechanisms. The formulation demonstrated excellent physicochemical characteristics, dermal safety, microbiological integrity, and storage stability, meeting all evaluated quality parameters.

The scientific evidence supports the rationale for using this combination of essential oils in headache, migraine, stress, nasal congestion, and musculoskeletal pain management. The multi-modal mechanism of action—encompassing peripheral analgesia, neurogenic anti-inflammation, central anxiolysis, decongestant, and rubefacient effects—positions this herbal roll-on as a comprehensive, patient-friendly, and economical therapeutic option. However, the translation of these findings into clinical practice requires rigorous pharmacokinetic characterization, standardization of raw material quality, and clinical validation through well-designed randomized controlled trials. The identified research gaps and future scope outlined in this review provide a structured roadmap for advancing this formulation from bench to bedside. With the global shift towards safer, natural, and sustainable therapeutics, herbal

roll-on preparations represent a promising frontier in integrative headache management.

REFERENCES

1. Ali, B., Al-Wabel, N. A., Shams, S., Ahamad, A., Khan, S. A., & Anwar, F. (2015). Essential oils used in aromatherapy: A systemic review. *Asian Pacific Journal of Tropical Biomedicine*, 5(8), 601–611. <https://doi.org/10.1016/j.apjtb.2015.05.007>
2. Bakkali, F., Averbeck, S., Averbeck, D., & Idaomar, M. (2008). Biological effects of essential oils—A review. *Food and Chemical Toxicology*, 46(2), 446–475. <https://doi.org/10.1016/j.fct.2007.09.106>
3. Bauer, K., Garbe, D., & Surburg, H. (2001). *Common fragrance and flavor materials: Preparation, properties and uses* (4th ed.). Wiley-VCH.
4. Borhani Haghighi, A., Motazedian, S., Rezaii, R., Mohammadi, F., Salarian, L., Pourmokhtari, M., ... & Petramfar, P. (2010). Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: A randomised, double-blind, placebo-controlled, crossed-over study. *International Journal of Clinical Practice*, 64(4), 451–456. <https://doi.org/10.1111/j.1742-1241.2009.02215.x>
5. Buchbauer, G. (2010). Biological activities of essential oils. *Flavour and Fragrance Journal*, 25(6), 407–426.
6. Cavanagh, H. M. A., & Wilkinson, J. M. (2002). Biological activities of lavender essential oil. *Phytotherapy Research*, 16(4), 301–308. <https://doi.org/10.1002/ptr.1103>
7. Chaieb, K., Hajlaoui, H., Zmantar, T., Kahla-Nakbi, A. B., Rouabhia, M., Mahdouani, K., & Bakhrouf, A. (2007). The chemical composition and biological activity of clove essential oil, *Eugenia caryophyllata* (*Syzygium aromaticum*): A short review. *Phytotherapy Research*, 21(6), 501–506. <https://doi.org/10.1002/ptr.2124>
8. Daniel, A. N., Sartoretto, S. M., Schmidt, G., Caparroz-Assef, S. M., Bersani-Amado, C. A., & Cuman, R. K. N. (2009). Anti-inflammatory and antinociceptive activities of eugenol essential oil in experimental animal models. *Brazilian Journal of Pharmacognosy*, 19(1B), 212–217.
9. Dhakad, A. K., Pandey, V. V., Beg, S., Rawat, J. M., & Singh, A. (2018). Biological, medicinal and toxicological significance of Eucalyptus leaf essential oil: A review. *Journal of the Science of Food and Agriculture*, 98(3), 833–848. <https://doi.org/10.1002/jsfa.8600>
10. Diener, H. C., Holle-Lee, D., Käseborn, M., & Nebe, A. (2019). Medication-overuse headache: Risk factors, pathophysiology, and management. *Nature Reviews Neurology*, 15(10), 575–588. <https://doi.org/10.1038/s41582-019-0224-8>
11. Edris, A. E. (2007). Pharmaceutical and therapeutic potentials of essential oils and their individual volatile constituents: A review. *Phytotherapy Research*, 21(4), 308–323. <https://doi.org/10.1002/ptr.2072>

12. Field, T., Diego, M., Hernandez-Reif, M., Cisneros, W., Feijo, L., Vera, Y., & Pickens, J. (2005). Lavender fragrance cleansing gel effects on relaxation. *International Journal of Neuroscience*, 115(2), 207–222. <https://doi.org/10.1080/00207450590519056>
13. Fluhr, J. W., Darlenski, R., & Surber, C. (2008). Glycerol and the skin: Holistic approach to its origin and functions. *British Journal of Dermatology*, 159(1), 23–34. <https://doi.org/10.1111/j.1365-2133.2008.08643.x>
14. Garg, A., Aggarwal, D., Garg, S., & Singla, A. K. (2010). Spreading of semisolid formulations: An update. *Pharmaceutical Technology*, 26(9), 84–102.
15. GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, 396(10258), 1204–1222. [https://doi.org/10.1016/S0140-6736\(20\)30925-9](https://doi.org/10.1016/S0140-6736(20)30925-9)
16. Göbel, H., Schmidt, G., & Soyka, D. (1994). Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algometric headache parameters. *Cephalalgia*, 14(3), 228–234. <https://doi.org/10.1046/j.1468-2982.1994.014003228.x>
17. Gupta, A., Jaiswal, J., & Gupta, D. (2020). Nanoemulsion based delivery systems for essential oils: A review. *Journal of Drug Delivery Science and Technology*, 60, 101944.
18. ICH. (2003). ICH Q1A(R2): Stability testing of new drug substances and products. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
19. Iscan, G., Kirimer, N., Kürkçüoğlu, M., Başer, K. H. C., & Demirci, F. (2002). Antimicrobial screening of *Mentha piperita* essential oils. *Journal of Agricultural and Food Chemistry*, 50(14), 3943–3946. <https://doi.org/10.1021/jf011476k>
20. Juergens, U. R., Engelen, T., Racke, K., Stober, M., Gillissen, A., & Vetter, H. (2003). Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine production in cultured human lymphocytes and monocytes. *Pulmonary Pharmacology & Therapeutics*, 17(5), 281–287. <https://doi.org/10.1016/j.pupt.2004.06.002>
21. Kehrl, W., Sonnemann, U., & Dethlefsen, U. (2004). Therapy for acute nonpurulent rhinosinusitis with cineole: Results of a double-blind, randomized, placebo-controlled trial. *Laryngoscope*, 114(4), 738–742. <https://doi.org/10.1097/00005537-200404000-00027>
22. Lambers, H., Piessens, S., Bloem, A., Pronk, H., & Finkel, P. (2006). Natural skin surface pH is on average below 5, which is beneficial for its resident flora. *International Journal of Cosmetic Science*, 28(5), 359–370. <https://doi.org/10.1111/j.1467-2494.2006.00344.x>
23. Linck, V. M., da Silva, A. L., Figueiro, M., Piato, A. L., Herrmann, A. P., Dupont, F., ... & Elisabethsky, E. (2009). Inhaled linalool-induced sedation in mice. *Phytomedicine*, 16(4), 303–307. <https://doi.org/10.1016/j.phymed.2008.08.001>
24. Lipton, R. B., Munjal, S., Alam, A., Buse, D. C., Fanning, K. M., Reed, M. L., & Schwedt, T. J. (2020). Migraine in America symptoms and treatment (MAST) study: Baseline study methods, treatment patterns, and gender differences. *Headache*, 58(9), 1408–1426.
25. Marriott, C., Martin, G. P., & Rowlands, C. C. (2010). Physical pharmacy and biopharmaceutical principles: Pharmaceutical application. Pharmaceutical Press.
26. McKay, D. L., & Blumberg, J. B. (2006). A review of the bioactivity and potential health benefits of peppermint tea (*Mentha piperita* L.). *Phytotherapy Research*, 20(8), 619–633. <https://doi.org/10.1002/ptr.1936>
27. Moss, M., Cook, J., Wesnes, K., & Duckett, P. (2010). Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. *International Journal of Neuroscience*, 113(1), 15–38. <https://doi.org/10.1080/00207450390161903>
28. Patel, T., & Bhatt, N. (2016). Essential oil safety in infants and children: Special considerations. *Journal of Clinical Pharmacology*, 56(2), 198–205.
29. Pazyar, N., Yaghoobi, R., Ghassemi, M. R., Kazerouni, A., Rafeie, E., & Jamshyadian, N. (2013). Jojoba in dermatology: A succinct review. *Giornale Italiano di Dermatologia e Venereologia*, 148(6), 687–691.
30. Perry, N., & Perry, E. (2006). Aromatherapy in the management of psychiatric disorders: Clinical and neuropharmacological perspectives. *CNS Drugs*, 20(4), 257–280. <https://doi.org/10.2165/00023210-200620040-00001>
31. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*, 26(11), 1261–1268. <https://doi.org/10.1038/nbt.1504>
32. Rang, H. P., Dale, M. M., Ritter, J. M., & Flower, R. J. (2020). *Pharmacology* (9th ed.). Elsevier.
33. Rao, G. N., Subbakrishna, D. K., & Kulkarni, G. B. (2017). Prevalence and burden of headache disorders in India: A systematic review. *Neurology India*, 65(3), 509.
34. Raut, J. S., & Karuppayil, S. M. (2014). A status review on the medicinal properties of essential oils. *Industrial Crops and Products*, 62, 250–264. <https://doi.org/10.1016/j.indcrop.2014.05.055>
35. Sasannejad, P., Saeedi, M., Shoeibi, A., Gorji, A., Abbasi, M., & Foroughipour, M. (2012). Lavender essential oil in the treatment of migraine headache: A placebo-controlled clinical trial. *European Neurology*, 67(5), 288–291. <https://doi.org/10.1159/000335249>
36. Sharma, V., Rana, M., & Gupta, A. (2020). Formulation and evaluation of herbal roll-on for headache relief. *International Journal of Pharmaceutical Sciences and Research*, 11(7), 3456–3462.
37. Sherkheli, M. A., Vogt-Eisele, A. K., Bura, D., Zur Borg, I. R. L., Gisselmann, G., & Hatt, H. (2010). Characterization of menthol inhibitory effects on TRPA1. *Journal of Pharmacy and Pharmaceutical Sciences*, 13(3), 315–326.

38. Stovner, L. J., Hagen, K., Linde, M., & Steiner, T. J. (2022). The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates. *The Journal of Headache and Pain*, 23(1), 34. <https://doi.org/10.1186/s10194-022-01402-2>
39. Takaki, I., Bersani-Amado, L. E., Vendruscolo, A., Sartoretto, S. M., Diniz, S. P., Bersani-Amado, C. A., & Cuman, R. K. N. (2008). Anti-inflammatory and antinociceptive effects of *Rosmarinus officinalis* L. essential oil in experimental animal models. *Journal of Medicinal Food*, 11(4), 741–746. <https://doi.org/10.1089/jmf.2007.0524>
40. Thiele, J. J., Hsieh, S. N., & Ekanayake-Mudiyanse, S. (2005). Vitamin E: Critical review of its current use in cosmetic and clinical dermatology. *Dermatologic Surgery*, 31(7), 805–813. <https://doi.org/10.1111/j.1524-4725.2005.31724>
41. Tisserand, R., & Young, R. (2014). *Essential oil safety: A guide for health care professionals* (2nd ed.). Churchill Livingstone.
42. Wagner, H., & Ulrich-Merzenich, G. (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. *Phytomedicine*, 16(2–3), 97–110. <https://doi.org/10.1016/j.phymed.2008.12.018>
43. World Health Organization. (2024). Headache disorders. WHO. <https://www.who.int/news-room/fact-sheets/detail/headache-disorders>